Pfizer Inc. ($PFE) Stock Forecast: Up 7.5% Today

What is Pfizer Inc.?

Pfizer Inc. (NYSE: PFE) is a leading pharmaceutical company known for its innovative drugs and vaccines. Today, the stock experienced a strong bullish movement in the market.

Why is Pfizer Inc. going up?

PFE stock is up 7.5% on Oct 1, 2025 19:41

• Pfizer's stock surged due to a significant agreement with the administration to reduce prescription drug prices, fostering optimism in the pharmaceutical sector.
• Granting Pfizer a three-year exemption from pharmaceutical tariffs by the administration enabled the company to provide medications at reduced prices, bolstering investor confidence.
• The agreement not only benefited Pfizer but also had broader implications for companies such as CVS Health, Eli Lilly, and UnitedHealth Group.
• Market response indicates that Pfizer's strategic decisions and alignment with government policies have positioned it favorably, leading to a bullish trend in its stock price.

PFE Price Chart

PFE Technical Analysis

PFE News

Moderna Stock Is Rallying Wednesday: What's Driving The Action? - Moderna ( NASDAQ:MRNA )

Moderna Inc ( NASDAQ:MRNA ) stock is trading higher Wednesday afternoon, lifted by positive sentiment across the pharmaceutical sector. The rally follows a landmark agreement Tuesday between Pfizer Inc ( NYSE:PFE ) and the Trump administration to lower prescription drug prices.

https://www.benzinga.com/trading-ideas/movers/25/10/47977556/moderna-stock-is-rallying-wednesday-whats-driving-the-action

Will Pfizer Head Higher? - Pfizer ( NYSE:PFE )

Shares of Pfizer Inc. ( NYSE:PFE ) continue to head higher on Wednesday, a day after the company announced that it has secured a three-year grace period from President Donald Trump's tariffs on pharmaceuticals. This will enable Pfizer to offer its medication at significantly discounted prices ...

https://www.benzinga.com/trading-ideas/technicals/25/10/47974840/stock-of-the-day-will-pfizer-head-higher

Pfizer's TrumpRx Pact Sends Shockwaves: Why UnitedHealth, Lilly And CVS Can't Look Away - CVS Health ( NYSE:CVS ) , Eli Lilly ( NYSE:LLY ) , Pfizer ( NYSE:PFE ) , UnitedHealth Group ( NYSE:UNH )

Pfizer Inc's ( NYSE:PFE ) deal with Washington isn't just a handshake in the Oval Office - it's a seismic jolt to America's drug-pricing game.

https://www.benzinga.com/trading-ideas/long-ideas/25/10/47971458/pfizers-trumprx-pact-sends-shockwaves-why-unitedhealth-lilly-and-cvs-cant-look-away

Mark Cuban Grades Trump's Online Drug Store 'B,' Plans To Give It An 'A' If These Changes Happen: 'Trump Gets All The Credit' - Pfizer ( NYSE:PFE )

Mark Cuban, the billionaire entrepreneur and investor, has given a cautious "B" grade to President Donald Trump's new online drug store venture, TrumpRx.gov. Cuban, the founder of Cost Plus Drugs, a direct-to-consumer online pharmacy, expressed his thoughts on Trump's new venture on X.

https://www.benzinga.com/news/health-care/25/10/47967300/mark-cuban-grades-trumps-online-drug-store-b-plans-to-give-it-an-a-if-these-changes-happen-trump

Trump's pharmaceutical tariff threat loses bite after Pfizer deal reassures drugmakers

Pfizer's deal with Trump was a relief to the pharma industry, signaling that drugmakers could strike similar deals that would make them immune to tariffs.

https://www.cnbc.com/2025/10/01/trump-pharmaceutical-tariffs-pfizer-deal.html

Trending Today

American Eagle Outfitters Inc. ($AEO) Stock Forecast: Down 7.1% Today

Hewlett Packard Enterprise Company ($HPE) Stock Forecast: Down 9.9% Today

The Travelers Companies Inc. ($TRV) Stock Forecast: Down 5.4% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Up 6.8% Today

XRP ($XRP) Crypto Forecast: Down 5.4% Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.1% Today

Immutable ($IMX) Crypto Forecast: Down 10.6% Today

PancakeSwap ($CAKE) Crypto Forecast: Down 8.7% Today

Cardano ($ADA) Crypto Forecast: Down 5.6% Today

Binance Coin ($BNB) Crypto Forecast: Down 5.1% Today

Pfizer Inc. Price History

04.03.2025 - PFE Stock was down 5.4%

• Despite positive news about expanding the use of its RSV vaccine in the EU and receiving endorsements for its blood cancer combo therapy in the UK, Pfizer (PFE) faced a bearish movement.
• The decline in PFE's stock could be attributed to the overall uncertainty in the pharmaceutical sector due to proposed tariffs on pharma imports, impacting various drug stocks including PFE, MRK, ABBV, and LLY.
• Investors are comparing Pfizer (PFE) with Johnson & Johnson (JNJ) and assessing which drug giant presents a better investment opportunity, leading to a shift in market sentiment towards JNJ over PFE.
• Although Pfizer (PFE) expects improvements in sales and profits in the future, the current market reaction suggests that investors are cautious about the company's performance in the near term, contributing to the bearish movement in its stock price.

24.01.2025 - PFE Stock was up 0.2%

• The bullish movement in Pfizer's stock today can be attributed to several factors:
• The discovery of a new coronavirus in China has led to a rise in vaccine stocks, including Pfizer, as investors anticipate increased demand for vaccines in response to potential outbreaks.
• Pfizer's decision to discontinue the hemophilia gene therapy Beqvez, which saw low adoption rates, could be viewed positively by investors as the company shifts its focus to more promising products like Hympavzi.
• Despite ongoing investigations into Pfizer's Board of Directors for potential breaches of fiduciary duties, the market seems to be focusing more on the company's product developments and potential for growth in the healthcare sector.

15.06.2025 - PFE Stock was down 2.4%

• Pfizer's stock price declined by 1.17% as the market rallied, indicating a bearish trend for the company.
• The announcement of a $1 billion net IRA impact in 2025 due to Medicare Part D changes likely contributed to investor concerns and the negative market reaction.
• The FDA's acceptance of GlaxoSmithKline's filing for expanded use of RSV vaccine in younger adults may have shifted some focus away from Pfizer, impacting its stock performance.
• Moderna's stock surging after receiving full FDA approval for its COVID-19 vaccine in pediatric patients could have also diverted investor attention from Pfizer, potentially leading to the bearish movement in Pfizer's stock price.

05.07.2025 - PFE Stock was up 5.0%

• Strong bullish movement attributed to impressive Q2 earnings, beating estimates with significant growth in earnings and revenues.
• Rising sales in oncology drugs like Vyndaqel, Comirnaty, and Paxlovid, as well as cost-cutting measures expected to save billions by 2027, fueled the positive market response.
• Optimism further boosted by the company's raised 2025 EPS guidance and expectations of continued strength in key products like Vyndaqel and Padcev.
• President Trump's ultimatum to lower drug prices may have influenced the overall positive sentiment, potentially benefiting companies like Pfizer in the long run.

05.07.2025 - PFE Stock was up 5.3%

• Pfizer reported better-than-expected Q2 earnings, with EPS beating consensus and sales rising by 10% year-over-year, driven by key products like Vyndaqel, Comirnaty, and Paxlovid.
• The company raised its 2025 EPS guidance and announced cost-cutting measures expected to save $7.7 billion by the end of 2027, which boosted investor confidence in the stock.
• Despite facing declines in some products like Eliquis, Ibrance, and Prevnar, Pfizer's overall performance and future outlook seem promising, leading to the bullish market movement.
• The negative news about Trump issuing an ultimatum to pharmaceutical companies to lower drug prices did not significantly impact Pfizer's stock, as the positive earnings report overshadowed external pressures.

30.08.2025 - PFE Stock was up 5.7%

• Pfizer's stock saw a surge following reports of an agreement with President Trump to lower drug prices voluntarily, showcasing a positive impact on the company's reputation and potential market growth.
• Despite legal challenges related to Depo-Provera brain tumor claims, the news did not notably affect the stock's performance today, with investors focusing on the favorable developments.
• The acquisition of Metsera by Pfizer for next-generation weight loss drugs is viewed as a strategic maneuver that could enhance innovation and research expenditure, bolstering the optimistic sentiment.
• Despite a recent stock price decline, today's bullish movement demonstrates resilience and investor confidence in Pfizer's future prospects, especially with the spotlight on a potential drug-pricing arrangement.

01.09.2025 - PFE Stock was up 7.7%

• The stock of Pfizer witnessed a significant surge in the market today.
• An agreement on drug pricing with President Donald Trump has fueled this bullish movement, indicating promising prospects for the company's future revenue and competitive position.
• Investor confidence in Pfizer received a boost from this agreement, which also eased industry concerns regarding potential tariff impacts, resulting in a positive market trend.
• Positive remarks from Mark Cuban regarding Trump's online pharmacy initiative and its potential enhancements may have contributed to the optimistic outlook on Pfizer's stock.
• The collaboration between Pfizer and the U.S. government to lower drug prices has not only enhanced the company's stock performance but has also underscored its dedication to addressing healthcare affordability challenges.

01.09.2025 - PFE Stock was up 7.4%

• Pfizer's stock experienced a bullish movement following reports of an agreement with President Donald Trump to lower drug prices. This news likely boosted investor confidence in the company's future prospects.
• The deal with Trump and the positive response from the pharmaceutical industry regarding Pfizer's tariff situation provided a favorable outlook for the company, leading to increased buying interest in the stock.
• Mark Cuban's assessment of Trump's online drug store venture and the upcoming court hearing over Depo-Provera brain tumor claims may have added some volatility to Pfizer's stock but did not deter the overall bullish sentiment driven by the drug pricing deal announcement.
• Overall, the market movement of Pfizer today can be attributed to a combination of positive news related to drug pricing agreements and potential challenges the company may face in the legal arena.

01.09.2025 - PFE Stock was up 7.5%

• Pfizer's stock surged due to a significant agreement with the administration to reduce prescription drug prices, fostering optimism in the pharmaceutical sector.
• Granting Pfizer a three-year exemption from pharmaceutical tariffs by the administration enabled the company to provide medications at reduced prices, bolstering investor confidence.
• The agreement not only benefited Pfizer but also had broader implications for companies such as CVS Health, Eli Lilly, and UnitedHealth Group.
• Market response indicates that Pfizer's strategic decisions and alignment with government policies have positioned it favorably, leading to a bullish trend in its stock price.

29.03.2025 - PFE Stock was up 3.2%

• Pfizer exceeded Q1 earnings expectations by a substantial margin, indicating robust financial performance.
• The implementation of cost-cutting strategies has enhanced profitability, despite a drop in sales.
• Optimism among investors surrounds Pfizer's non-COVID medications driving sales growth, highlighting diversification and strength in the company's product lineup.
• The collaboration with Guardant Health for the development of new cancer treatments has likely bolstered investor confidence in Pfizer's innovative ventures, contributing to the positive market trend.

08.06.2025 - PFE Stock was up 2.2%

• Pfizer's strong bullish momentum is linked to its consistent trading performance above the 50-day average, reflecting robust positive momentum amid challenges like declines in COVID revenues and patent-related risks.
• The recent decision by the FDA chief to restrict COVID-19 vaccine approval to seniors and high-risk groups is thought to have positively influenced Pfizer's stock, considering its significant role in the vaccine market.
• Moderna's stock surge subsequent to the CDC's expanded RSV vaccine recommendations might have also played a part in the positive outlook for the pharmaceutical industry, indirectly benefiting Pfizer.
• The decrease in sales of legacy drugs for Bristol Myers (BMY) potentially underscored Pfizer's resilience and dedication to innovative products, potentially drawing investors' attention to Pfizer's stock.

25.07.2025 - PFE Stock was down 2.1%

• Pfizer's (PFE) stock price sharply declined today, despite a recent uptrend in the past month, potentially indicating profit-taking or shifting market sentiment.
• Despite reports of major investors taking bullish positions on Pfizer, the market movement appeared bearish today. It's crucial to recognize that multiple factors beyond investor sentiment can influence market dynamics.
• The bearish trend could be linked to overall market movements, industry-specific updates, or internal developments impacting Pfizer's stock negatively.
• Investors are advised to monitor forthcoming announcements or updates regarding Pfizer to gain insights into the causes behind today's market downturn.